Thermo Fisher Q3 2026 revenue up 9% to $12.14B; adjusted EPS $6.68, up 15%

THERMO FISHER SCIENTIFIC INC.

Revenue $12.14B vs $11.12B a year ago, +9% reported with 6% organic growth.
GAAP diluted EPS $4.64 (+9%); adjusted EPS $6.68 (+15%).
GAAP operating income $2.26B (+17%), margin 18.6% vs 17.4%; adjusted operating income $2.97B (+15%), margin 24.5% vs 23.3%.
Completed previously announced divestiture of the microbiology business during the quarter.
Launched Orbitrap Isora mass spectrometer, EMPAD G2 detector, FDA-cleared EliA CTD 13 Screen and Ion 560 chip; updated 2026 guidance to come on the 7:00 a.m. ET call.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.